Purchase Order 75N95A18P00130

<p>The National Institute of Neurological Disorders and Stroke awarded a purchase order to Illumina, Inc. for $14,960.88 on February 8, 2018, with ultimate completion by April 28, 2018. No set-aside applied. Place of performance is Bethesda, Maryland. The order covers sequencing instruments, reagents, consumables, or bioinformatics software under firm fixed pricing, with no originating solicitation identified in the source.</p>

<p>The National Institute of Neurological Disorders and Stroke issued a $26,597.20 delivery order to Illumina, Inc. on August 19, 2020, for genetic sequencing and genomic analysis equipment and consumables.</p> <p>Place of performance is Bethesda, MD. The order was firm fixed price with no set-aside designation and an ultimate completion date of September 2, 2020. The source does not name a parent IDIQ or GWAC vehicle for this delivery order.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $24,418.80 on November 30, 2018. The order is firm fixed price with no set-aside and carries an ultimate completion date of December 28, 2018. Place of performance is San Diego, California. The purchase order covers sequencing instruments, reagents, consumables, or bioinformatics software consistent with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $20,269.44 on September 21, 2017, with an ultimate completion date of October 31, 2017. Place of performance is San Diego, California. The order is firm fixed price with no set-aside applied. The purchase order procures sequencing instruments, reagents, consumables, or bioinformatics software consistent with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded a $292,320 firm fixed price delivery order to Illumina, Inc. for eighteen NOVASEQ X SERIES 25B REAGENT KITS (300 CYCLES). The place of performance is Chevy Chase, Maryland and the completion date is August 26, 2024. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis. This delivery order was issued...

<p>The NIH Clinical Center awarded a purchase order to Illumina, Inc. for $19,112.76 on July 17, 2019, with an ultimate completion date of October 31, 2019. The order is a firm fixed price procurement with no set-aside. Work is performed in San Diego, California. The purchase order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio serving federal research and diagnostic agencies.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $17,735.76 on December 21, 2018, with completion by December 25, 2019. The order is a firm fixed price acquisition with no set-aside. Work is performed at Bethesda, Maryland. The purchase order procures DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product lines serving federal health and research agencies.</p>

The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded a $15,200 delivery order to Illumina, Inc. under an unspecified contract vehicle. The delivery order is for the provision of REAGENT - INF METHYLATIONEPIC V2.0 KITS to support genomic research efforts. Performance will occur in San Diego, California over a two-month period concluding in late September 2023. The pricing structure is firm fixed price. No...

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $10,752.18 on July 3, 2018. The order, placed under firm fixed pricing with no set-aside, calls for sequencing-related products and services. Place of performance is San Diego, California. The order carried an ultimate completion date of July 3, 2018.</p>

<p>The National Institute of Neurological Disorders and Stroke issued a delivery order to Illumina, Inc. on September 20, 2017, for an Infinium OmniExpressExome-8 V1.4 kit (16-sample and 48-sample configurations) with a ceiling value of $8,182.85.</p> <p>Place of performance is Bethesda, MD 20892. The order, priced on a firm fixed-price basis, has an ultimate completion date of September 2, 2020. No set-aside was applied.</p>